Background: New direct-acting antiviral agents (DAAs) have shown great efficacy and tolerability in clinical trials and real-life cohorts. However, data are scarce regarding efficacy and safety in cirrhotic HCV/HIV-coinfected patients.
Introduction
Since their introduction in 2011, the use of new direct-acting antiviral agents (DAAs) has enhanced the efficacy and safety of HCV treatment in comparison with previous interferon-based regimens.
1,2 Similar results in regard to the safety and efficacy of DAAs have also been reported from clinical trials in HIVcoinfected patients. [3] [4] [5] [6] Thus, DAA combinations are the current standard of treatment for hepatitis C chronic infection both in HCV-monoinfected and HCV/HIV-coinfected patients. 7, 8 V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Rates of sustained virological response 12 weeks after stopping treatment (SVR12) .95% are achieved in the majority of patients treated with new DAA combinations. [3] [4] [5] 9 However, the likelihood of treatment success is lower in some groups, such as treatmentexperienced cirrhotic patients compared with either non-cirrhotic or treatment-naive patients. 9, 10 Indeed, this issue seems to have a greater impact in genotype (Gt) 3, irrespective of history of previous treatment, 11 and Gt-1a infection when treated with some DAA combinations. 12 Safety and efficacy results have been obtained among HCV/ HIV-coinfected patients and several studies have shown similar SVR12 rates and tolerability compared with HCV-monoinfected subjects. [3] [4] [5] However, cirrhotic patients represent less than a quarter of the patients included in the majority of the studies. 3, 4, 6 Therefore, it is clinically relevant to generate more information in regard to the efficacy and safety of new DAA combinations in cirrhotic HCV/HIV-coinfected patients.
Herein, we conducted a prospective multicentre cohort analysis in cirrhotic HCV/HIV-coinfected patients starting HCV treatment based on oral DAAs to analyse the efficacy and safety of these new regimens in this difficult-to-treat population.
Patients and methods

Patients
We conducted a multicentre cohort study including all adult cirrhotic HCV/HIV-coinfected patients that started HCV treatment in 13 hospitals in Spain between January and December 2015. Patients were included if they met the following inclusion criteria: (i) they had a diagnosis of liver cirrhosis; (ii) they received HCV treatment based on DAAs according to drug availability and physician discretion; and (iii) they had a controlled HIV infection with stable ART (defined as HIV-RNA ,25 copies/mL while receiving the same ART for at least 6 months prior to starting HCV treatment). The diagnosis of cirrhosis was made based on: (i) liver stiffness measurement (LSM) .14.6 kPa, 13 measured by transient elastography (TE) (FibroScan V R , Echosens, France); and (ii) sonographic findings (such as signs of portal hypertension, heterogeneous echotexture, surface nodularity, ascites and/or portosystemic collaterals), endoscopic (portal gastropathy and/or oesophageal varices) and/or clinical evidence of cirrhosis (prior history of hepatic decompensation). Participants in any clinical trial were excluded from the study.
TE was performed according to the FibroScan V R manufacturer's instructions and as described elsewhere.
14 Briefly, the technician performed at least 10 consecutive measurements with a minimum success rate of 80% and an IQR variation ,30% between measurements.
HCV viral load quantification technique varied according to the centre. The assays used were: Roche V R Cobas 6800 System real-time PCR with a limit of quantification of 15 IU/mL; Cepheid Xpert V R HCV Viral Load real-time PCR with a limit of quantification of 10 IU/mL and Abbott RealTime V R HCV real-time PCR with a limit of quantification of 15 IU/mL.
Drugs commercially available in Spain at the beginning of the study were sofosbuvir and simeprevir. Daclatasvir was introduced in March 2015, and sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir combinations became available in April 2015. Patients infected with Gt-3 treated with pegylated IFN plus ribavirin and sofosbuvir were included in the analysis, as it was the preferred regimen for the treatment of these patients at the beginning of the study. There were no limitations regarding ART drugs used. Regimens used were decided by the treating physician based on drug-drug interactions, history of ART and drug resistance.
On-treatment visits were made at day 0, weeks 4 and 12, and at end of treatment. Additional visits during treatment were performed at the physician's discretion. A post-treatment visit was done 12 weeks after therapy finalization.
Ethics
This study was done in accordance with local ethical and legal requirements. The study protocol and procedures (VHB-VHC-2015-01) were approved by the local ethics committee and The Spanish Agency for Medication and Healthcare Products (AEMPS).
Variables
Demographic data (age, sex and race), HIV characteristics (current ART, CD4! cell count and HIV-RNA levels) and HCV-related data (risk factor for infection, genotype, prior treatment and type of response, previous hepatic decompensation, Child-Pugh score; TE at baseline and at week 12 after stopping treatment; DAAs used; dates of treatment initiation and completion; use of ribavirin and dose modification; HCV-RNA levels at baseline, treatment weeks 4 and 12, and post-treatment week 12) were recorded in an electronic database and extracted for analysis.
Outcome measures
The primary endpoint was SVR12 (HCV-RNA below the limit of quantification). Secondary objectives included: treatment safety, assessed as the percentage of patients who withdrew treatment due to toxicity and/or hepatic decompensation; SVR12 according to the regimen used and HCV-Gt; and changes in TE and Child-Pugh score, at week 12 after HCV treatment.
Statistical analysis
Categorical variables are described as numbers (proportions) and continuous variables as medians and IQR unless otherwise specified. The t-test for paired data and Wilcoxon's signed rank test were used to compare quantitative variables; the v 2 test and Fisher's exact test were used to compare categorical variables. Treatment effectiveness was calculated by intentionto-treat analysis, considering missing data and discontinuations as treatment failures. For SVR12 rates, 95% CIs were calculated. An on-treatment analysis, excluding patients who discontinued treatments prematurely, was also performed.
Predictors of treatment failure were identified by binomial logistic regression analysis including all factors considered clinically relevant, using a conditional step-forward selection method with an inclusion criterion of P , 0.05. IBM SPSS statistics software for Windows (Version 21; IBM, Armonk, NY, USA) was used for statistical analyses. All P values were two-tailed.
Results
Baseline characteristics
A total 201 patients started treatment with DAAs during the study period. Of them, 170 were included in this study. Thirty-one patients were excluded from the final analysis as they were either still on treatment or had not completed post-treatment evaluation (Table 1) . Most patients were male (n " 125; 73.5%), Caucasian (n " 167; 98.2%) and had been intravenous drug users (n " 138; 81.2%). All but two patients (1.2%) were on ART and almost 90% (n " 152) had undetectable HIV-RNA, with a median CD4! count of 513 cells/mm 3 (IQR 320-697). The distribution of HCV-Gt was: Gt-1a, 68 (40%) patients; Gt-1b, 21 (12.4%); Gt-2, 1 (0.6%); Gt-3, 26 (15.3%); Gt-4, 47 (27.6%); Efficacy of DAAs in cirrhotic HCV/HIV-coinfected patients JAC mixed Gt-1a/1b, 1 (0.6%) and Gt-1/4, 1 (0.6%); non-subtyped Gt-1, 3 (1.8%). There were two (1.2%) patients with non-typeable Gt. Median TE at baseline was 20.6 kPa (IQR 16.1-33.7) and log 10 plasma HCV-RNA 6.1 IU/mL (IQR 5.7-6.5). According to the ChildPugh score, 127 (74.7%) of the patients evaluated had class A, 21 (12.4%) had class B and 1 (0.6%) had class C. A prior episode of hepatic decompensation was recorded in 28 (16.5%) patients (12 ascites; 8 encephalopathy; 4 with variceal bleeding; and 4 with jaundice). There were 89 (52.3%) pretreated patients, of whom 40.4% (n " 36) were non-responders. Twenty-three (13.5%) patients had been previously treated with a PI plus pegylated IFN and ribavirin.
The most commonly used DAA-based regimens were: sofosbuvir/ledipasvir ! ribavirin, 25.3% (n " 43 patients); sofosbuvir ! simeprevir ! ribavirin, 20% (n " 34); sofosbuvir/ledipasvir, 15.3% (n " 26); and sofosbuvir ! daclatasvir ! ribavirin, 14.7% (n " 25). Overall, 123 (72.4%) patients received a ribavirin-containing regimen (Table 1) .
HCV treatment outcome
Overall, 92.9% (158/170) of patients achieved an SVR12 (95% CI 88.1-95.9). By on-treatment analysis, SVR12 was achieved in 157/ 164 patients (95.7%; 95% CI 91.4-97.9). According to HCV genotype, SVR12 was: Gt-1a, 92.6% (95% CI 83.9-96.8); Gt-1b, 100% (95% CI 84.5-100); Gt-3, 100% (95% CI 87.1-100) and Gt-4, 89.4% (95% CI 77.4-95.4). There were no SVR12 differences between genotypes (v 2 test, P " 0.5) ( Table 2 ). The only patient with Gt-2, treated with sofosbuvir ! ribavirin for 12 weeks, experienced a viral relapse at week 12 after treatment.
SVR12 was statistically significantly lower in treatmentexperienced as compared with treatment-naive patients: 88.8% versus 97.5%; P " 0.026. Between group differences were driven by a poorer SVR12 among pretreated patients with Gt-1a (87.2% versus 100%; P " 0.045). Among Gt-4-infected patients, a trend for a lower SVR12 rate was also seen in treatment-experienced as compared with naive patients (83.3% versus 93.1%; P " 0.29) (Figure 1) . Treatment failure occurred in 12 patients [treatment relapse, 7 (4.1%); lost to follow-up, 2 (1.2%); and 1 (0.6%) of each of the following: toxicity-related discontinuation; hepatic decompensation; Table 3 . Three out of seven relapses occurred among patients infected with Gt-1a (n " 2) or Gt-4 (n " 1) treated with sofosbuvir ! simeprevir + ribavirin for 12 weeks. The remaining four relapses occurred in three patients treated with sofosbuvir/ledipasvir ! ribavirin, one patient infected with Gt-1a and two with Gt-4 with previous failure to pegylated IFN plus ribavirin treatment, and in a treatment-experienced patient with Gt-2 treated with sofosbuvir ! ribavirin.
In the univariate analysis, prior HCV treatment was associated with a higher risk of treatment failure (OR 5; 95% CI 1.1-23.6; P " 0.04). Furthermore, patients with Child-Pugh class B or C showed a trend to lower SVR12 rates (OR 3.9; 95% CI 0.9-17.5; P " 0.08). However, in a multivariate analysis adjusted by HCV genotype, IL28B status (CC versus non CC), Child-Pugh class (A versus B/C), prior HCV treatment (yes versus no), platelets, albumin, a-fetoprotein, HCV-RNA, DAA regimen, duration of the treatment (12 versus 24 weeks) and ribavirin use (yes versus no), no variable was independently associated with SVR12.
Safety analysis
On-treatment hepatic decompensation was seen in four (2.4%) patients: two cases with encephalopathy and two with ascites. Regimens received by these patients were sofosbuvir ! simeprevir (one patient), sofosbuvir/ledipasvir + ribavirin (two patients) and sofosbuvir ! daclatasvir ! ribavirin (one patient).
Liver decompensation in three of them was managed by modification of diuretic treatment and anti-encephalopathy measures, while maintaining anti-HCV therapy. The remaining patient receiving sofosbuvir ! simeprevir was admitted to hospital with severe encephalopathy at week 4 and HCV treatment was stopped. At this timepoint HCV-RNA was undetectable. Following therapy for hepatic encephalopathy, the clinical condition improved, and the patient was discharged. However, HCV relapse was detected 4 weeks later.
One additional patient, treated with sofosbuvir/ledipasvir ! ribavirin, discontinued treatment at week 6 due to gastrointestinal disturbances. Despite the short duration of treatment, HCV-RNA remained undetectable 24 weeks later.
Twenty (16.3%) patients treated with ribavirin needed dose modification, mainly due to anaemia (n " 17). Only two (1.6%) patients had to stop ribavirin due to severe adverse effects: gastrointestinal disturbances (n " 1, discontinued all anti-HCV therapy) and pancreatitis (n " 1).
Liver stiffness and liver function tests
At week 12 after treatment discontinuation, TE was performed in 33 (19.4%) patients. Values of LSM decreased by a mean of 5.6 kPa (95% CI 1.8-9.2; P " 0.004), as compared with baseline. No differences were seen between patients who underwent paired LSM and the remaining patients regarding Child-Pugh class, DAA regimens used or HCV genotype (data not shown).
Furthermore, statistically significant increases in platelet count (18527/lL; 95% CI 2163-34891; P " 0.03) and albumin level (0.3 g/dL; 95% CI 0.2-0.4; P , 0.001) were observed. Twelve (57.1%) patients with baseline Child-Pugh B class improved their liver function to a Child-Pugh A score. Three (1.8%) patients presented hepatic decompensation after treatment completion and before the SVR12 visit; all of them had a prior history of hepatic decompensation. No liver-related death or transplantation occurred during the study. 
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Discussion
In our prospective multicentre cohort study, 93% of cirrhotic HCV/HIV-coinfected patients treated with DAA-based regimens achieved SVR12. This high rate of viral eradication obtained in real-life conditions in a hard-to-treat population (all patients had cirrhosis, 16% of them with prior decompensation and 52% pretreated) is in agreement with that observed in cirrhotic, HCVmonoinfected and HCV/HIV-coinfected patients that were included in clinical trials. 3, 4, 9 The risk of viral relapse in our study was very low. Indeed, only 4.3% (7/164) of patients who completed treatment experienced a viral relapse during follow-up. Three relapses occurred among patients treated with sofosbuvir ! simeprevir + ribavirin for 12 weeks. Combination of sofosbuvir plus simeprevir for 12 weeks has proven suboptimal for the treatment of patients infected with Gt-1a with compensated cirrhosis. 15 Although extending therapy to 24 weeks, with or without ribavirin, is considered a therapeutic alternative for these patients, 7, 8 no evidence is available in regard to the efficacy of this regimen for the treatment of cirrhotic patients, and the efficacy might be highly compromised in patients with the Q80K mutation. In addition, two of those patients with Gt-1a who relapsed on sofosbuvir ! simeprevir + ribavirin had previously failed on a boceprevir-or telaprevir-containing regimen. Therefore, NS3 resistance mutants conferring resistance to simeprevir could be present at baseline.
Furthermore, despite being considered a therapeutic alternative in some international guidelines, 7, 16 very scarce information is available in regard to the efficacy of sofosbuvir ! simeprevir + ribavirin for the treatment of cirrhotic patients infected with Gt-4. O v e r a l l G e n o t y p e Regarding Gt-2 treatment failure with sofosbuvir ! ribavirin, although this combination has been until recently the preferred regimen for the treatment of Gt-2, it is no longer recommended in current guidelines 7, 8 due to the suboptimal virological response in pretreated cirrhotic patients 18 and the development of new drug combinations, such as sofosbuvir/velpatasvir, with higher activity against this genotype.
19
It is worth noting that all cirrhotic patients with Gt-3 included in our study (n " 26; 12 of them pretreated) attained SVR12. Considering that cirrhotic patients infected with Gt-3 have become the most difficult-to-treat population in the DAA era, these data are outstanding. The vast majority of patients with Gt-3 included in our study (17/26) received sofosbuvir ! daclatasvir + ribavirin for 24 weeks, which may explain these results.
In the ALLY-3! trial, including patients with Gt-3 and advanced fibrosis (F3 or F4), SVR12 rates in patients with cirrhosis were 83% (15/18) after 12 weeks of treatment with sofosbuvir ! daclatasvir, and 89% (16/18) after 16 weeks of the same regimen. In treatment-experienced cirrhotic patients, SVR12 rates were 88% (14/16) and 86% (12/14) , respectively. 20 No clinical trial evaluated the efficacy of extending the duration of this regimen longer than 16 weeks. Nonetheless, data from cohort studies 21, 22 suggest that these patients may benefit from extending treatment duration up to 24 weeks. Although the optimal duration of sofosbuvir ! daclatasvir and ribavirin for the treatment of these patients remains to be elucidated, guidelines recommend prolongation up to 24 weeks to avoid the risk of viral relapse. 7, 8 Sofosbuvir/velpatasvir combination, recently approved for the treatment of HCV infection, has shown very promising results in cirrhotic patients infected with Gt-3. In the ASTRAL 3 study, in patients with Gt-3 and compensated cirrhosis, SVR12 rates were 93% (40/43) and 89% (33/37) in treatment-naive patients and treatment-experienced patients, respectively, after 12 weeks of treatment with this combination. 19 Whether or not the efficacy of this combination might be improved with the addition of ribavirin is currently under evaluation in a clinical trial. 23 In our study, seven patients were treated with pegylated IFN plus ribavirin in combination with a DAA (three infected with Gt-3 and four with Gt-4) and all of them achieved SVR12. Pegylated IFN plus ribavirin and sofosbuvir was until recently considered an alternative regimen for the treatment of cirrhotic patients with Gt-3. 24, 25 However, IFN-free DAA combinations are now considered the standard of care for all patients with chronic HCV infection. 7, 8 DAA-based regimens showed good safety and tolerability during the study. Two patients (1.2%) discontinued treatment due to adverse events and 2.4% of patients (n " 4) presented hepatic decompensation during treatment, leading to DAA discontinuation in one case. In keeping with our data, 2% of patients with cirrhosis included in clinical trials with DAAs discontinued therapy. 12, 26, 27 The use of some NS3/4A PIs has been associated with higher risk of hepatic decompensation in cirrhotic patients. 28, 29 In our study, 60 patients were treated with a PI-containing regimen. Of them, only one treated with simeprevir developed hepatic decompensation during treatment, and no patient treated with paritaprevir/ritonavir/ombitasvir + dasabuvir (n " 13) suffered hepatic decompensation. However, due to concerns of hepatotoxicity, paritaprevir/ritonavir/ombitasvir with or without dasabuvir is contraindicated in patients with decompensated cirrhosis and close monitoring is recommended in patients with compensated cirrhosis who start treatment with this combination. 8, 30, 31 Anaemia was observed among 16% of patients treated with ribavirin-containing regimens, and the ribavirin dose was modified in 20 patients.
In our study, an improvement in liver function was observed when evaluated using biomarkers, such as platelet count or albumin level. Indeed, half of patients with baseline Child-Pugh class B improved to class A. Furthermore, liver stiffness decreased by a mean of 5.6 kPa at week 12 after finishing therapy.
Our study has some limitations. Baseline resistance mutation testing was not performed and we were unable to analyse the impact of resistance-associated variants on treatment outcome, especially whether the presence of Q80 mutation increased the risk of viral relapse among patients with Gt-1a treated with sofosbuvir ! simeprevir + ribavirin. Also, more than three-quarters of the patients in our study were treated with either sofosbuvir/ledipasvir + ribavirin or sofosbuvir ! simeprevir ! ribavirin or sofosbuvir ! daclatasvir ! ribavirin. Few patients received paritaprevir/ ritonavir/ombitasvir + dasabuvir regimens. Thus, limited information was obtained from our study in regard to the efficacy and safety of these regimens. However, all but one patient infected with Gt-1 (10/10) or Gt-4 (2/3) treated with paritaprevir/ritonavir/ombitasvir and paritaprevir/ritonavir/ombitasvir ! dasabuvir, respectively, achieved SVR12. In addition, decompensated cirrhosis was registered in only 16 patients analysed in our study, a population with lower SVR12 rates. Finally, only 20% of the patients underwent LSM at week 12 after treatment discontinuation, because some centres did not have TE available at the moment of the visit or expected to evaluate liver stiffness at week 24 after treatment finalization. However, it is worth noting the decrease observed in those patients in whom LSM was available. Therefore, further evaluation will be needed during follow-up of these patients.
In summary, in this cohort of HCV/HIV-coinfected patients with compensated cirrhosis, treatment with DAA-based regimens was very safe and achieved a high rate of viral eradication. Our data reinforce current recommendations to treat coinfected patients with the same regimens as HCV-monoinfected patients.
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